Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis

The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients

(2012) D. Solomon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis

(2012) Geert D'Haens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Guidelines for the management of inflammatory bowel disease in adults

(2011) C. Mowat et al.   GUT

Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis*

(2011) Sunanda Kane et al.   INFLAMMATORY BOWEL DISEASES

In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness

(2010) Srini Tenjarla et al.   ADVANCES IN THERAPY

Does Treatment Schedule Matter? Once Daily versus Divided Doses of 5-ASAs

(2010) Sunanda Kane   DIGESTIVE DISEASES

A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective

(2010) Nic Brereton et al.   JOURNAL OF MEDICAL ECONOMICS

Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX®with Asacol®

(2009) C. PRANTERA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Oral 5-ASA Therapy in Ulcerative Colitis

(2009) William J. Sandborn   JOURNAL OF CLINICAL GASTROENTEROLOGY

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations

(2008) G. R. LICHTENSTEIN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

(2008) M A Kamm et al.   GUT

Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis

(2008) Michael A. Kamm et al.   INFLAMMATORY BOWEL DISEASES

European evidence-based Consensus on the management of ulcerative colitis: Current management

(2008) S.P.L. Travis et al.   Journal of Crohns & Colitis